Literature DB >> 24947767

Cryptococcus neoformans meningoencephalitis in a patient with polyarteritis nodosa.

Vladimír Buchta1, Petr Prášil, Marcela Vejsová, Roman Mottl, Radka Kutová, Marcela Drahošová, Stanislav Plíšek.   

Abstract

Case of 59-year-old male with chronic obstructive pulmonary disease and a number of comorbidities, who has developed meningoencephalitis caused by Cryptococcus neoformans var. grubii with polyarteritis nodosa diagnosed during hospitalization, was presented. Before evidence of meningoencephalitis, the patient was being treated with ketoconazole and low doses of fluconazole (200 mg/day) for alleged candidiasis. The dosage was increased (800 mg/day) following laboratory diagnosis of C. neoformans based on positive latex agglutination test and biochemical identification of encapsulated yeast isolated from the blood and CSF. Later, the yeast identification was confirmed by sequencing analysis. Owing to inadequate clinical response, fluconazole therapy was switched to voriconazole (400 mg/day) and later to intravenous amphotericin B (1.0 mg/kg per day). Despite of a temporary stabilization and improvement, which correlated with decline of cryptococcal antigen titers (from 1:1024 to 1:8), after 6 weeks, the patient's underlying condition deteriorated due to severe pancolitis and serious nosocomial bacterial infections. The patient died of multiorgan failure several days later. Our case demonstrates a possible connection between the development of life-threatening cryptococcosis and an autoimmune vasculitis disease and emphasizes that the outcome of the management of cryptococcal meningoencephalitis is highly dependent on early diagnosis, adequate treatment, including dosage, and last but not least control of underlying disease and risk factors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24947767     DOI: 10.1007/s12223-014-0328-0

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.099


  51 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.

Authors:  E Dannaoui; M Abdul; M Arpin; A Michel-Nguyen; M A Piens; A Favel; O Lortholary; F Dromer
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy.

Authors:  P G Pappas; J R Perfect; G A Cloud; R A Larsen; G A Pankey; D J Lancaster; H Henderson; C A Kauffman; D W Haas; M Saccente; R J Hamill; M S Holloway; R M Warren; W E Dismukes
Journal:  Clin Infect Dis       Date:  2001-07-26       Impact factor: 9.079

4.  Prevalence of serotype D in Cryptococcus neoformans isolates from HIV positive and HIV negative patients in Italy.

Authors:  A M Tortorano; M A Viviani; A L Rigoni; M Cogliati; A Roverselli; A Pagano
Journal:  Mycoses       Date:  1997-11       Impact factor: 4.377

Review 5.  Idiopathic CD4 lymphocytopenia.

Authors:  Ulrich A Walker; Klaus Warnatz
Journal:  Curr Opin Rheumatol       Date:  2006-07       Impact factor: 5.006

6.  Idiopathic CD4+ lymphocytopenia and systemic vasculitis.

Authors:  G Bordin; M Ballaré; S Paglino; P Ravanini; D Dulio; M C Malosso; R Boldorini; A Monteverde
Journal:  J Intern Med       Date:  1996-07       Impact factor: 8.989

7.  Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection.

Authors:  Livio Pagano; Luana Fianchi; Cecilia Caramatti; Domenico D'Antonio; Lorella Melillo; Morena Caira; Luciano Masini; Giuseppe Todeschini; Corrado Girmenia; Bruno Martino; Saverio Cinieri; Pietro Martino; Albano Del Favero
Journal:  Haematologica       Date:  2004-07       Impact factor: 9.941

Review 8.  Fluconazole resistance in cryptococcal disease: emerging or intrinsic?

Authors:  Jenny Wan Sai Cheong; Joe McCormack
Journal:  Med Mycol       Date:  2012-09-19       Impact factor: 4.076

9.  Beta-2-microglobulin in the cerebrospinal fluid of patients with infections of the central nervous system.

Authors:  N A Peterslund; F T Black; J P Geil; C E Mogensen
Journal:  Acta Neurol Scand       Date:  1989-12       Impact factor: 3.209

Review 10.  Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.

Authors:  Angela Loyse; Françoise Dromer; Jeremy Day; Olivier Lortholary; Thomas S Harrison
Journal:  J Antimicrob Chemother       Date:  2013-06-20       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.